Manufacture of antibodies for tumor-selective binding to CD47

A bispecific antibody with low CD47 and high CD20 affinity selectively targets tumor cells, overcoming limitations of existing therapies by inducing phagocytosis and cytotoxicity, thus improving treatment efficacy in hematological malignancies and B-cell disorders.

KR103000411B1Active Publication Date: 2026-08-05CELGENE CORP
3 Cites 0 Cited by

Patent Information

Application Number
KR1020217035862
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-04-05
Filing Date
2020-04-03
Publication Date
2026-08-05
Estimated Expiration
2040-04-03

AI Technical Summary

Technical Problem

Current therapies targeting the CD47-SIRPα interaction for cancer treatment face challenges such as the need for combination therapy, tissue sinks, hematological toxicities, and immune responses leading to reduced efficacy and toxicity, particularly in hematological malignancies and B-cell disorders.

Method used

Development of a bispecific antibody with low affinity for CD47 and high affinity for CD20, selectively binding to tumor cells and activating phagocytosis, complement-dependent cytotoxicity, and antibody-dependent cytotoxicity, while minimizing binding to normal cells.

Benefits of technology

The bispecific antibody effectively induces macrophage-mediated phagocytosis and cytotoxicity in tumor cells, reducing toxicity and enhancing therapeutic efficacy in hematological malignancies and B-cell disorders.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

An antibody is provided comprising at least one Fab portion that binds to CD47 and at least one Fab portion that binds to the tumor-associated antigen (TAA) CD20; wherein the Fab portion that binds to CD47 exhibits low affinity for CD47; wherein the Fab portion that binds to CD20 exhibits high affinity for CD20; wherein the antibody selectively binds to CD47 in tumor cells and blocks CD47 interaction with SIRPα but does not exhibit substantial binding to CD47 in normal cells.
Need to check novelty before this filing date? Find Prior Art